Initiation or maintenance of beta-blocker therapy in patients hospitalized for acute heart failure
- 484 Downloads
Background Beta-blockers have been recommended for patients with heart failure and reduced ejection fraction for their long-term benefits. However, the tolerance to betablockers in patients hospitalized with acute heart failure should be evaluated. Objective To estimate the proportion of patients hospitalized with acute heart failure who can tolerate these agents in clinical practice and compare the clinical outcomes of patients who can and cannot tolerate treatment with beta-blockers. Setting Two reference hospitals in cardiology. Methods Retrospective cohort study of consecutive patients hospitalized for acute heart failure between September 2008 and May 2012. Population-based sample. During the study period, 325 patients were admitted consecutively, including 194 individuals with an acute heart failure diagnosis and systolic left ventricular dysfunction and ejection fraction ≤45 %, who were candidates for the initiation or continuation of beta-blockers. Main outcome measure The percentage of patients intolerant to beta-blockers and the clinical characteristics of patients. Results On admission, 61.8 % of patients were already using beta-blockers, and 73.2 % were using beta-blockers on discharge. During hospitalization, 85 % of patients used these agents for some period. The main reasons for not using betablockers were low cardiac output syndrome (24.4 %), bradycardia (24.4 %), severe hypotension or shock (17.8 %), and chronic obstructive pulmonary disease (13.3 %). Patients who were intolerant or did not use a beta-blocker had a longer hospital stay (18.3 vs. 11.0 days; p < .001), greater use of vasoactive drugs (41.5 vs. 16.3 %; p < .001, CI 1.80–7.35), sepsis and septic shock (RR = 3.02; CI 95 % 1.59–5.75), and higher mortality rate during hospitalization (22.6 vs. 2.9 %; p < .001; CI 3.05–32.26). Conclusion Beta-blockers could be used in 73.2 % of patients hospitalized for acute heart failure. Patients who can not tolerate BB presented a higher frequency of adverse clinical outcomes including frequency of sepsis, use of vasoactive drugs, average length of hospitalization, and death.
KeywordsAcute heart failure Beta-blockers Brazil
We thank the Cardiology residents and undergraduate students who participated in data collection: Rafael Britto Fernandes, Nathalie Meira Castro Aguiar, Geraldo José Bensabath Filho, Paula Graziela Figueredo, Elaine Alves Santos Tessie. We thank the President of the Cardiology Bahia Foundation, Alvaro Rabelo Jr., for creating a suitable academic environment and developing electronic media that enabled a faster data review.
This study was partially funded by the scientific initiation program of the Federal University of Bahia, CNPQ, and FAPESB.
Conflicts of interest
There are no conflicts of interest to declare.
- 1.McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.CrossRefPubMedGoogle Scholar
- 2.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013;128(16):1810–52.CrossRefPubMedGoogle Scholar
- 12.Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail. 2010;12(11):1253–60.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European society of cardiology guidelines? Evidence from 12,440 patients of the esc heart failure long-term registry. Eur J Heart Fail. 2013;15(10):1173–84.CrossRefPubMedGoogle Scholar
- 14.Tarantini L, Cioffi G, Opasich C, Di Lenarda A, Pulignano G, Del Sindaco D, et al. Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure. Ital Heart J. 2004;5(6):441–9.PubMedGoogle Scholar
- 17.Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand heart failure research collaborative group. Circulation. 1995;92(2):212–218Google Scholar
- 22.Atwater BD, Dai D, Allen-Lapointe NM, Al-Khatib SM, Zimmer LO, Sanders GD, et al. Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. Am Heart J. 2012;164(5):750–755.e1.Google Scholar